A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500094-14-00

Acronym

SGNALPV-001

Enrollment

Registered

2022-07-26

Start date

2022-11-08

Completion date

2023-10-09

Last updated

2023-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical cancer, Endometrial cancer, Gastric cancer, Gastroesophageal junction carcinoma, gastroesophageal junction [GEJ] carcinoma, Malignant extragonadal GCT with the exception of pure teratomas or tumors with primaries arising from the central nervous system (CNS), Malignant ovarian GCT with the exception of pure teratomas, Malignant testicular germ cell tumor (GCT) with the exception of pure teratomas, Non-small cell lung cancer (NSCLC), Ovarian cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

Denmark, Netherlands, Spain, Sweden

Outcome results